Anti‐amyloid antibody treatments for Alzheimer's disease
Open accessAbstract
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease directed against amyloid‐β. This is a joint statement of the European Association of Neurology and the European Psychiatric Association. After numerous unsuccessful endeavors to create a disease‐modifying therapy for Alzheimer's disease, substantial and consistent evidence supporting the clinical effectiveness of monoclonal antibodies aimed at amyloid‐β is finally emerging. The latest trials not only achieved their primary objective of slowing the progression of the disease over several months but also demonstrated positive secondary clinical outcomes and a decrease in amyloid‐β levels as observed through positron emission tomography scans. Taken as a whole, these findings mark a significant breakthrough by substantiating that reducing amyloid‐β yields tangible clinical benefits, beyond mere changes in biomarkers. Concurrently, the regular utilization of the new generation of drugs will determine whether statistical efficacy translates into clinically meaningful improvements. This may well signify the dawning of a new era in the development of drugs for Alzheimer's disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the EMERGE trial (NCT 02484547), aducanumab at a high dose significantly reduced the dementia rating score CDR-SB.
“In the EMERGE trial (NCT 02484547), aducanumab at a high dose significantly reduced dementia rating score CDR-SB (clinicaltrials.org, for a review see [14]).”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 26 · Cited by 106
Research works printed but not linked: 1
- [24]Genentech. Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer's Disease. Genentech; 2022. Accessed September 10, 2023. https://www.gene.com/media/press‐releases/14974/2022‐11‐13/genentech‐provides‐update‐on‐phase‐iii‐g
- Authors
- Perneczky, R., Dom, G., Chan, A., Falkai, P., & Bassetti, C.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- University of Antwerp (BE)
- University of Bern (CH)
- LMU Klinikum (DE)
- Corresponding author
- Perneczky, Robert
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2023-09-11
- Volume
- 31
- Issue
- 2
- Pages
- e16049-e16049
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- PMC
- PMC11235913
- OpenAlex
- W4386623568
- Cited by
- 106
- References
- 26
- Citations by year
- 2026: 30 · 2025: 48 · 2024: 27 · 2023: 1
- FWCI
- 18.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Neurology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion, other-oa)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by-nc)
- DZNE Pub (submittedVersion, cc-by-nc)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- BORIS (University Library Bern) (submittedVersion, cc-by-nc)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (NIHR203321)
- European Commission (101132356)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, anti-amyloid monoclonal antibodies, amyloid-beta, disease-modifying therapy, clinical trials, amyloid PET, drug efficacy
- MeSH terms
- Alzheimer Disease, Antibodies, Monoclonal, Humans, Biomarkers, Amyloid beta-Peptides, Treatment Outcome, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
